| Field | Specification |
|---|---|
| Target | |
| Applications | |
| Molecular weight | |
| Molecular formula | C27H38ClN9 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
4A7C-301 is a blood-brain barrier-permeable Nurr1 agonist that binds Nurr1-LBD with IC50 values of 48.22 nM ([3H]-CQ competition assay) and 107.71 nM (TR-FRET assay), activating Nurr1 transcriptional activity with an EC50 of 6.53 μM and showing an EC50 of approximately 0.2 μM in N27-A dopaminergic cells. By binding directly to Nurr1-LBD, it enhances Nurr1 transcriptional function and restores Nurr1 protein levels reduced by MPP+ or αSyn, while alleviating oxidative stress and mitochondrial dysfunction, protecting midbrain dopaminergic neurons, inhibiting microglial activation, and restoring impaired autophagic flux[1]. The manufacturer notes its use in neuroprotection and Parkinson's disease research. It is supplied as a white to light yellow solid (C27H38ClN9, MW 524.10) at 99.86% purity.
Physical & Chemical Properties
| Molecular Formula | C27H38ClN9 |
|---|---|
| Molecular Weight | 524.10 g/mol |
| Purity | 99.86% |
| Appearance | Solid |
| Color | White to light yellow |
| SMILES | ClC1=CC=C2C(NCCNC3=NC(N4CCN(CC)CC4)=CC(N5CCN(CC)CC5)=N3)=CC=NC2=C1 |
| Target | Nurr1, Nurr1-LBD |
| Signaling Pathway | Vitamin D Related/Nuclear Receptor |
| Solubility | In Vitro: DMSO: 140 mg/mL (267.12 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
Nurr1 6.53 μM (EC50) |
Nurr1-LBD 48.22 nM (IC50, [3H]-CQ competition assay) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 140 mg/mL (267.12 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
4A7C-301 binds Nurr1-LBD directly, giving IC50 values of 48.22 ± 22.05 nM in the [3H]-CQ competition assay and 107.71 ± 14.14 nM in the TR-FRET competition assay[1]. Transcriptional activity of Nurr1 is activated by 4A7C-301 with an EC50 of 6.53 μM and a maximum induction of 18.12-fold, and an EC50 of approximately 0.2 μM is seen in N27-A dopaminergic cells[1]. In primary rat VM neuron-glia co-cultures, 4A7C-301 (5-1000 nM; 30 min pre-treatment) protects TH+ dopaminergic neurons in a dose-dependent manner against injury induced by MPP+ (0.5 μM) or LPS (15 ng/mL); the maximal neuroprotective effect appears at 500 nM after 7 days of treatment[1].
Cell Viability Assay[1]
| Cell Line | N27-A cells with Nurr1 OE or KD |
|---|---|
| Concentration | 4A7C-301: 1 μM; MPP+: 1 mM |
| Incubation Time | Overnight |
| Result | Increased cell viability in a Nurr1-dependent manner. |
In Vivo
In MPTP-induced male mice, 4A7C-301 (5 mg/kg/day; i.p.; daily; 16 days) gives neuroprotection, improves both motor and non-motor olfactory deficits, lessens neuroinflammation, and restores dopamine levels, without inducing dyskinesia-like behaviors[1]. In male mice overexpressing either αSynWT or αSynA53T, neuropathological abnormalities are ameliorated, motor and olfactory dysfunctions are improved, and dopamine levels are also restored by 4A7C-301 (5 mg/kg/day; i.p.; daily; 5 weeks), with greater potency than CQ[1].
| Animal Model | C57BL/6 J (male, 8-10 weeks old, 25-30 g, subchronic MPTP-induced Parkinson’s disease model)[1] |
|---|---|
| Dosage | 5 mg/kg/day |
| Administration | i.p.; daily; 16 days |
| Result | Rescued MPTP-induced motor deficits in rotarod, pole, and cylinder tests to a degree comparable to higher doses of CQ and L-DOPA. Restored olfactory dysfunction impaired by MPTP lesion. Detected no abnormal involuntary movements (AIMs, dyskinesia-like behaviors). Significantly retained tyrosine hydroxylase-positive (TH+) fibers in the striatum, TH+ dopamine neurons, and NeuN+ neurons in the substantia nigra compared to MPTP-only group. Significantly reduced Iba-1+ activated microglia in both the striatum and substantia nigra. Restored dopamine levels in both the striatum and substantia nigra. |
| Animal Model | C57BL/6 J (male, 8-10 weeks old, 25-30 g, AAV2-mediated wild-type α-synuclein and mutant α-synuclein overexpression Parkinson’s disease model)[1] |
|---|---|
| Dosage | 5 mg/kg/day |
| Administration | i.p.; daily; 5 weeks |
| Result | Improved motor deficits in cylinder, rotarod, and pole tests with greater potency than CQ in both αSynWT- and αSynA53T-induced mice. Rescued olfactory dysfunction in both αSynWT- and αSynA53T-induced mice. Significantly prevented the loss of TH+ and NeuN+ neurons in the substantia nigra and TH+ fibers in the striatum in both αSynWT- and αSynA53T-induced mice. Significantly reduced phosphorylated αSyn at serine 129 (αSynS129) in both αSynWT- and αSynA53T-induced mice. Restored dopamine levels in both the striatum and substantia nigra in both models. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Comparative Profiling and Chemogenomics Application of Chemical Tools for NR4A Nuclear Receptors. J Med Chem 2025 Oct 9;68(19):19955-19970. PMID: 40968635
